Search
Nuvation Bio Inc
NUVBAdd to Watchlist
4.320USD
-0.395-8.37%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
1.50BMarket Cap
LossP/E TTM
More Details of Nuvation Bio Inc Company
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
Nuvation Bio Inc Info
Ticker SymbolNUVB
Company nameNuvation Bio Inc
IPO dateJul 01, 2020
CEOHung (David T)
Number of employees220
Security typeOrdinary Share
Fiscal year-endJul 01
Address1500 Broadway
CityNEW YORK
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code10036
Phone13322086102
Websitehttps://www.nuvationbio.com/
Ticker SymbolNUVB
IPO dateJul 01, 2020
CEOHung (David T)
Company Executives of Nuvation Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
59.28M
-1.69%
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
200.00K
+50.00%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+64.10%
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
61.37K
--
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
12.67K
+42.40%
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
10.00K
--
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Lead Independent Director
Lead Independent Director
5.00K
--
Dr. Gary Hattersley, Ph.D.
Dr. Gary Hattersley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
59.28M
-1.69%
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
200.00K
+50.00%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+64.10%
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
61.37K
--
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Hung (David T)
17.02%
Fidelity Management & Research Company LLC
14.62%
Decheng Capital LLC
7.45%
BlackRock Institutional Trust Company, N.A.
5.81%
Vanguard Capital Management, LLC
3.34%
Other
51.75%
Shareholders
Shareholders
Proportion
Hung (David T)
17.02%
Fidelity Management & Research Company LLC
14.62%
Decheng Capital LLC
7.45%
BlackRock Institutional Trust Company, N.A.
5.81%
Vanguard Capital Management, LLC
3.34%
Other
51.75%
Shareholder Types
Shareholders
Proportion
Investment Advisor
31.16%
Individual Investor
18.62%
Venture Capital
10.51%
Investment Advisor/Hedge Fund
9.28%
Hedge Fund
7.77%
Research Firm
2.03%
Bank and Trust
0.26%
Pension Fund
0.23%
Family Office
0.08%
Other
20.06%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
421
228.36M
65.58%
-32.85M
2025Q4
389
225.55M
65.98%
-37.34M
2025Q3
355
228.75M
66.72%
-24.74M
2025Q2
346
279.19M
82.03%
-27.71M
2025Q1
346
276.31M
81.30%
-31.14M
2024Q4
336
290.52M
86.58%
+4.56M
2024Q3
324
278.55M
83.07%
+36.83M
2024Q2
323
221.78M
89.68%
-2.09M
2024Q1
305
194.38M
89.06%
-41.04M
2023Q4
290
194.02M
89.00%
-35.90M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Hung (David T)
60.28M
17.39%
+500.00K
+0.84%
Jun 16, 2025
Fidelity Management & Research Company LLC
50.91M
14.69%
+854.51K
+1.71%
Dec 31, 2025
Decheng Capital LLC
25.95M
7.49%
--
--
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
20.23M
5.84%
+250.74K
+1.26%
Dec 31, 2025
Omega Fund Management, LLC
8.08M
2.33%
-750.00K
-8.49%
Dec 31, 2025
Laurion Capital Management LP
7.85M
2.27%
-1.85M
-19.09%
Dec 31, 2025
State Street Investment Management (US)
5.86M
1.69%
-230.40K
-3.78%
Dec 31, 2025
Geode Capital Management, L.L.C.
5.71M
1.65%
-175.46K
-2.98%
Dec 31, 2025
Wang (Junyuan Jerry)
4.42M
1.27%
-56.36K
-1.26%
Nov 11, 2024
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
State Street SPDR S&P Pharmaceuticals ETF
2.51%
Virtus LifeSci Biotech Clinical Trials ETF
1.95%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.79%
Tema Oncology ETF
1.66%
ALPS Medical Breakthroughs ETF
0.74%
iShares U.S. Pharmaceuticals ETF
0.46%
iShares Micro-Cap ETF
0.25%
iShares Health Innovation Active ETF
0.24%
Avantis US Small Cap Equity ETF
0.16%
iShares Biotechnology ETF
0.11%
View more
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.51%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.95%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.79%
Tema Oncology ETF
Proportion1.66%
ALPS Medical Breakthroughs ETF
Proportion0.74%
iShares U.S. Pharmaceuticals ETF
Proportion0.46%
iShares Micro-Cap ETF
Proportion0.25%
iShares Health Innovation Active ETF
Proportion0.24%
Avantis US Small Cap Equity ETF
Proportion0.16%
iShares Biotechnology ETF
Proportion0.11%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
